News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Acorda Therapeutics (ACOR) Announces Public Offering Of Convertible Senior Notes Due 2021



6/17/2014 12:53:45 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced its intention to offer, subject to market and other conditions, $300 million principal amount of convertible senior notes due 2021 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission ("SEC") today. Acorda also intends to grant the underwriter an option to purchase up to an additional $45 million principal amount of Notes to cover over-allotments, if any.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES